In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show?

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show?

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Does your genomic profiling service update their supporting data frequently enough to capture the latest changes in practice recommendations?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Jianming Xu, MD

Professor Jianming Xu, MD

Affiliated Hospital Cancer Center
Academy of Military Medical Sciences
Beijing, China